GCG and type 2 diabetes mellitus: The benefit of GLP-1 RA in the management of visceral obesity has been well studied in patients with underlying T2D and these medications have been shown to significantly reduce visceral fat and hepatic fat content with improved glycemic control in this population [67–69].